This is the third competing proposal submitted for In Vivo Cellular and Molecular Imaging Center (ICMIC) PSO funding from Memorial Sloan-Kettering Cancer Center (ICMIC-3). ICMIC-3 seeks to continue the productivity of ICMICs-1 and-2 for advancing Molecular Imaging (Ml) in cancer. ICMICs-1 and -2 led to new tools for Ml and the discovery of novel features of cancer biology, as described in 125 original research papers;including development of 5 novel gene expression imaging (GEI) vectors, 10 new radiotracers, including 3 T-cell tracers;5 FDA IND's and 6 clinical protocols. Our vision for ICMIC-3 is "cancer biology integrated with real-time, noninvasive imaging for application in individual patient care and management". Our research plan includes 4 Research Projects (RP's: RP1 Imaging T-cell Targeting and Function in Human Cancer;RP2 Oncogene Induced Changes in Metabolism;RP3 Imaging the Effects of Oncoprotein-Targeted Inhibitors on Tumor Growth and Metabolism;and RP4 Refining Antiandrogen Therapy for Prostate Cancer through Positron-Emission-Tomography);2 Developmental Projects (DPs;DP-A Radiolabeling of HSP90 Inhibitors for Small Animal In Vivo Brain Imaging of Glioblastoma Multiforme;DP-B Imaging mesothelin chimeric receptor T-cell targeting in mesothelioma);and, 3 Specialized Resources (SRs;Chemistry &Radiochemistry, Gene Transfer and Quantitative Imaging). The ICMIC-3 research plan leverages the most innovative and clinically relevant prior discoveries/ developments and includes: RP1: GMP production of chimeric T-cells which target PSMA, an antigen in prostate cancer, based on GEI, for imaging in man (Ponomarev/Blasberg);RP2: multimodality metabolomic imaging with novel MRI/S and PET technology (Koutcher);RP3;pharmacologic dissection of the biology and clinical benefit of inhibiting the PI3K and Ras/ERK signal transduction pathways in melanoma and thyroid cancer (Rosen/Santos);RP4: genome wide RNA profiling for discovery of molecular determines of Ml androgen receptor targeting and glycolysis, through the use of novel mouse models of prostate cancer, and novel AR inhibitor drugs (Mellinghoff/Sawyers/Larson);DP-A: development of true tracers for Purine-based HSP90 inhibitors which cross blood brain barrier in glioma (Chiosis/Mellinghoff/Lewis);and DP-B: Chimeric T-cells with tumoricidal and targeting properties for mesothelin in mesothelioma (Sadelain/Riviere). In summary, we have shaped ICMIC-3 to closely adhere to the goals of PAR 09-157.

Public Health Relevance

ICMIC-3 will lead to better quality and length of life for cancer patients by tailoring Molecular Imaging to optimize individual patient management. Molecular Imaging will lead to a deeper understanding of the biology of how drugs affect transfer of growth signals in the tumor cell, leading to improved treatment regimens that avoid resistance resulting in an improved chance of remission and cure in prostate and thyroid cancer and melanoma.

National Institute of Health (NIH)
National Cancer Institute (NCI)
Specialized Center (P50)
Project #
Application #
Study Section
Special Emphasis Panel (ZCA1-SRLB-9 (M1))
Program Officer
Menkens, Anne E
Project Start
Project End
Budget Start
Budget End
Support Year
Fiscal Year
Total Cost
Indirect Cost
Sloan-Kettering Institute for Cancer Research
New York
United States
Zip Code
Cheal, Sarah M; Xu, Hong; Guo, Hong-fen et al. (2014) Preclinical evaluation of multistep targeting of diasialoganglioside GD2 using an IgG-scFv bispecific antibody with high affinity for GD2 and DOTA metal complex. Mol Cancer Ther 13:1803-12
de Biasi, Andreas R; Villena-Vargas, Jonathan; Adusumilli, Prasad S (2014) Cisplatin-induced antitumor immunomodulation: a review of preclinical and clinical evidence. Clin Cancer Res 20:5384-91
Vargas, Hebert Alberto; Wassberg, Cecilia; Fox, Josef J et al. (2014) Bone metastases in castration-resistant prostate cancer: associations between morphologic CT patterns, glycolytic activity, and androgen receptor expression on PET and overall survival. Radiology 271:220-9
Adusumilli, Prasad S (2014) Translational immunotherapeutics: chemoimmunotherapy for malignant pleural mesothelioma. Cancer 120:3268-71
Eguchi, Takashi; Kadota, Kyuichi; Park, Bernard J et al. (2014) The new IASLC-ATS-ERS lung adenocarcinoma classification: what the surgeon should know. Semin Thorac Cardiovasc Surg 26:210-22
Zhang, Hanwen; Huang, Ruimin; Pillarsetty, NagaVaraKishore et al. (2014) Synthesis and evaluation of 18F-labeled benzylguanidine analogs for targeting the human norepinephrine transporter. Eur J Nucl Med Mol Imaging 41:322-32
Cheal, Sarah M; Punzalan, Blesida; Doran, Michael G et al. (2014) Pairwise comparison of 89Zr- and 124I-labeled cG250 based on positron emission tomography imaging and nonlinear immunokinetic modeling: in vivo carbonic anhydrase IX receptor binding and internalization in mouse xenografts of clear-cell renal cell carcino Eur J Nucl Med Mol Imaging 41:985-94
Zhang, Hanwen; Huang, Ruimin; Cheung, Nai-Kong V et al. (2014) Imaging the norepinephrine transporter in neuroblastoma: a comparison of [18F]-MFBG and 123I-MIBG. Clin Cancer Res 20:2182-91
Beattie, Bradley J; Pentlow, Keith S; O'Donoghue, Joseph et al. (2014) A recommendation for revised dose calibrator measurement procedures for 89Zr and 124I. PLoS One 9:e106868
Lee, Ming-Ching; Buitrago, Daniel H; Kadota, Kyuichi et al. (2014) Recent advances and clinical implications of the micropapillary histological subtype in lung adenocarcinomas. Lung Cancer Manag 3:245-253

Showing the most recent 10 out of 119 publications